06 // Questions
AOD-9604 FAQ: Mechanism, Safety, and the Failed Obesity Trial
Direct answers to the questions people actually ask about AOD-9604, each cited where it makes a quantitative claim.
Does AOD9604 raise IGF-1 like HGH?
No. AOD-9604 is designed not to bind the growth-hormone receptor, so it does not raise IGF-1 the way intact growth hormone does — the basis for its "gh-receptor-sparing" framing [1][3]. Non-clinical evaluation also found it free of genotoxic and toxicological concerns in rats and primates, with a very short intravenous half-life of about 3 minutes [6].
Does AOD9604 affect insulin or blood sugar levels?
AOD-9604 was designed to avoid growth hormone's insulin-resistance effects by sparing the GH receptor [1]. In older mechanistic work, certain C-terminal hGH fragments raised blood glucose and insulin in rats, and the 178-191-containing peptides reduced insulin sensitivity — which helped identify which fragments carry diabetogenic activity [21]. No clinically meaningful glucose effect was reported in the human tolerability program [5].
Does AOD9604 preserve muscle mass while reducing fat?
There is no human evidence for either claim. Across about six trials of roughly 900 obese adults, oral AOD-9604 did not produce statistically significant weight loss versus placebo, so a fat-versus-muscle benefit was never demonstrated [5][12]. Users also generally report no change in strength, recovery, or muscle, consistent with a molecule that does not engage the growth-hormone receptor.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide modelled on the C-terminal region of human growth hormone (residues 176/177-191) with an added N-terminal tyrosine [3]. In fat cells it inhibits new-fat synthesis (via acetyl-CoA carboxylase) and up-regulates beta-3 adrenergic receptor expression [4][1], while sparing the growth-hormone receptor so it does not raise IGF-1 [1][3].
What does the peptide AOD9604 do?
In fat cells the AOD9604 peptide inhibits acetyl-CoA carboxylase to reduce new-fat synthesis and up-regulates beta-3 adrenergic receptor expression, increasing fat oxidation [4][1]. After 14 days of chronic dosing, obese mice lost body weight and fat [1]. In humans, however, it did not produce significant weight loss in the pivotal obesity trial [12].
Does AOD-9604 actually work?
In animals, yes — it reduced body weight and fat in obese mice [1][2]. In humans, no demonstrated benefit: across roughly six trials of about 900 obese adults, AOD-9604 did not show statistically significant weight loss versus placebo, and the obesity program was discontinued around 2007 [5][12]. The "fat-loss peptide" marketing runs ahead of the null human evidence [13].
How does AOD-9604 work?
It acts on fat cells. After 14 days of chronic dosing, AOD-9604 increased beta-3 adrenergic receptor RNA in obese mice and reduced body weight and fat; in beta3-AR knockout mice the chronic effect was abolished while acute fat oxidation persisted [1]. It also inhibits acetyl-CoA carboxylase to cut new-fat synthesis [4], all without engaging the growth-hormone receptor [3].
Is AOD-9604 FDA approved?
No. AOD-9604 is not FDA-approved for any indication [12]. The Metabolic Pharmaceuticals anti-obesity program was discontinued after the pivotal Phase IIb trial failed its primary endpoint. AOD-9604 was reviewed by the FDA Pharmacy Compounding Advisory Committee in December 2024 (docket FDA-2024-N-4777) regarding 503A compounding eligibility; that status should be independently verified [14].
Is AOD-9604 safe?
Human trials in about 900 obese adults reported a safety and tolerability profile indistinguishable from placebo, and non-clinical work found no genotoxic or toxicological concerns [5][6]. But the data are short — the longest published trial ran about 24 weeks, with no long-term surveillance — and it is investigational and not approved, so chronic and rare risks remain unknown [6].
Why was AOD-9604 discontinued as a pharmaceutical drug?
Because it did not work for its intended use. The pivotal Phase IIb obesity trial did not show statistically significant weight loss versus placebo, so Metabolic Pharmaceuticals discontinued the obesity development program around 2007 [12]. Strong rodent fat-metabolism data did not translate into clinical weight-loss efficacy — a common pattern for obesity drug candidates [13][14].
How does AOD9604 stimulate lipolysis without affecting the HGH receptor?
AOD-9604 is the C-terminal fat-metabolism fragment of growth hormone, so it carries the lipid-metabolism activity (acetyl-CoA carboxylase inhibition, beta3-AR up-regulation) without the receptor-binding region of the whole hormone [3][4][1]. Because it does not bind the growth-hormone receptor, it does not raise IGF-1 or trigger growth hormone's broader effects [1][3].
What is the half-life of AOD9604?
About 3 minutes after intravenous injection in a pig pharmacokinetic model [6]. The intact peptide is cleared rapidly, degrading by sequential removal of amino acids from the N-terminus in a cascade fashion [6]. Subcutaneous human pharmacokinetics have not been published in peer-reviewed literature.
Is AOD9604 orally bioavailable or does it have to be injected?
It was developed and tested as an orally dosed agent — oral tablets/capsules were the primary route in the Metabolic Pharmaceuticals human obesity program, and oral absorption was demonstrated in non-clinical work [5][6]. Other routes studied include intravenous (human Phase I and pig PK), intraperitoneal (mice), and intra-articular (the rabbit cartilage model) [6].
Does AOD9604 work by activating beta-3 adrenergic receptors?
Beta-3 adrenergic receptor (beta3-AR) signalling is central to its chronic effect. AOD-9604 up-regulated beta3-AR RNA in obese mice, and in beta3-AR knockout mice the chronic weight/fat response was abolished while acute fat oxidation persisted — so the long-term effect depends on functional beta3-AR [1]. It also inhibits acetyl-CoA carboxylase to reduce new-fat synthesis [4].
What are the side effects of AOD9604?
In the human trials, side effects were reported as indistinguishable from placebo, with none of the adverse effects tied to full-length growth hormone [5]. Real-world reports are mostly the absence of a noticeable effect, plus occasional injection-site redness or irritation — a generic reaction to subcutaneous injection. Long-term human safety data are limited [6].
Is AOD9604 banned in competitive sports?
Yes. As a growth-hormone fragment, AOD-9604 falls under the WADA Prohibited List, Section S2 (peptide hormones, growth factors and mimetics), and is prohibited at all times in sport [15]. Dedicated mass-spectrometric assays can detect it [16][17]. Athletes should treat it as a prohibited substance regardless of vendor claims to the contrary.
Is AOD9604 a steroid?
No. AOD-9604 is a peptide — a short chain of amino acids — and the C-terminal fat-metabolism fragment of growth hormone [3]. It has no androgenic steroid mechanism. It acts on fat cells by inhibiting new-fat synthesis and up-regulating beta-3 adrenergic receptor expression [4][1], not through any steroid pathway.
What happened in the AOD9604 Phase IIb clinical trial?
The pivotal Phase IIb obesity trial did not demonstrate statistically significant weight loss versus placebo [12]. Across the broader program of roughly six trials in about 900 obese adults, tolerability resembled placebo, but the efficacy endpoint was not met, and Metabolic Pharmaceuticals discontinued the obesity development program around 2007 [5][12].
How much weight can you lose on AOD9604 peptide?
The human evidence does not support a weight-loss figure. Across about six trials of roughly 900 obese adults, AOD-9604 did not produce statistically significant weight loss versus placebo [5][12]. The most common real-world report is no noticeable fat loss, consistent with the null trials. No human dose or expected result can be honestly stated.
Does AOD9604 help with cartilage repair and osteoarthritis?
Only in preclinical work. In a collagenase-induced knee osteoarthritis model in 32 rabbits, weekly intra-articular injection of 0.25 mg AOD-9604 per knee (with or without hyaluronic acid) for 4-7 weeks reduced cartilage-degeneration scores versus saline [10]. There are no published human osteoarthritis trials of AOD-9604 itself, so the joint evidence remains animal-only.
What is the mechanism of action of AOD9604?
AOD-9604 inhibits acetyl-CoA carboxylase to reduce de novo fat synthesis [4] and up-regulates beta-3 adrenergic receptor expression in white adipose tissue, increasing fat oxidation [1]. The chronic weight/fat effect requires functional beta3-AR signalling [1]. It spares the growth-hormone receptor, so it does not raise IGF-1 [1][3].
Where do you inject AOD-9604?
This site does not provide injection or dosing instructions. In research, AOD-9604 has been studied by several routes — oral and intravenous in humans, intraperitoneal in mice, and intra-articular in the rabbit cartilage model [5][6]. Reported injection-site reactions are generic to subcutaneous peptide injection rather than specific to the molecule.